In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form of epilepsy, scientists have developed a new gene replacement therapy in mice that could lead to more effective treatments in humans. The new therapy, a collaboration between researchers at the Allen Institute and Seattle Children’s Research Institute, alleviated symptoms and led to long-term recovery without toxicity, side effects, and death.
